以下文章转载自:
American Journal of Neuroradiology
Presurgical Mapping with fMRI and DTI: Soon the Standard of Care?
The technique of fMRI has been around for over 30 years, and DTI for about 15 years. The first application of fMRI was by Ogawa et al, in 1990. In a rat model, this team was able to manipulate the blood oxygen level–dependent (BOLD) signal by inducing changes in deoxyhemoglobin concentrations with insulin-induced hypoglycemia and anesthetic gases. About a year later, Kwong and Belliveau published the first images of cerebral areas that responded to visual stimulation and vision-related tasks.
DTI was first described by Basser et al, who were experimenting on a voxel-by-voxel characterization of 3D diffusion profiles, which took into account anisotropic effects (instead of eliminating them, as in standard DWI). Tractography (or fiber tracking) was developed by applying statistical models to DTI data to obtain anatomic fiber bundle information.
Although both fMRI and DTI are now currently available in most scanners, well beyond the framework of academic institutions and research protocols, these techniques are not quite considered “standard of care.” Indeed, the processes that govern the translation of new technology into clinical practice are complex. Even more complex are the processes that lead to establishing clinical practice as standard of care, particularly at a time when established patterns of care delivery are being increasingly challenged and economic difficulties affect all aspects of society, certainly including health care.
However, some challenges, especially with fMRI, go back to basic cerebrovascular physiology. The cerebrovascular response to neuronal activation, also referred to as “functional hyperemia,” was first recognized in 1890 by Roy and Sherrington, who initially proposed a metabolic hypothesis to the phenomenon, ie, mediation via release from neurons of vasoactive agents in the extracellular space. The major role of astrocytes as key intermediaries in the neurovascular response — being interposed between blood vessels and neuronal synapses via their foot processes as modeled in the “tripartite synapse model” of the neurovascular unit — has since been recognized. Although complex, astrocyte response to changes in synaptic activity is primarily mediated by glutamate receptors through changes in intracellular Ca2+ concentration.
In fMRI, contrast is based on the BOLD effect, which reflects local shifts of deoxygenated-to-oxygenated hemoglobin ratios due to local increases in blood flow in excess of oxygen utilization following brain activity. As a result, the foundation of the fMRI BOLD signal is based on local changes in cerebral blood flow that are not linearly related to the metabolic changes inducing the flow change.
Therefore, BOLD fMRI rests on 3 major approximations: 1) the technique does not directly reflect neural activity, ie, generation and propagation of action potentials, synaptic transmission, or neurotransmitter release/uptake; 2) the changes in BOLD signal originate from that portion of the vasculature experiencing the greatest change in oxygen concentration, which occurs in the venules in the immediate vicinity of the active neurons; and 3) more importantly, fMRI signal relies on intact “neurovascular coupling,” the phenomenon that links neural activity to metabolic demand and blood flow changes.
The main reason fMRI is clinically useful most of the time is that under most circumstances neurovascular coupling remains fully intact, unaltered by confounding disorders that can interfere with this relationship. However, it has long been known that neuronal activation results in local blood flow increases that exceed local oxygen consumption, so that the oxygen utilized may constitute a small fraction of the amount delivered. Under normal conditions, the oxygen concentration in draining venules increases during neuronal activation. The original researchers who discovered this phenomenon named it “neurovascular uncoupling” or “neurovascular decoupling.” From a medical perspective, “uncoupling” or “decoupling” implies a pathologic condition, suggesting something abnormal about tissue that demonstrates this phenomenon. More recently, researchers have preferred the term “functional hyperemia” to describe the phenomenon. In fact, when there is interference with the mechanism producing functional hyperemia, the term "neurovascular uncoupling" has been re-applied, albeit with a completely opposite meaning from that originally used. Impairment in the flow response leads to neurovascular uncoupling and a reduced BOLD signal in response to neural activity, which can lead to false-negative errors in fMRI maps.
John Ulmer, reporting on a series of 50 patients, found that although accurate cortical activation could be demonstrated most of the time, various cerebral lesions could cause false negatives in fMRI results when compared with other methods of functional localization, suggesting contralateral or homotopic reorganization of function. He further suggested that pathologic mechanisms such as direct tumor infiltration, neovascularity, cerebrovascular inflammation, and hemodynamic effects from high-flow vascular lesions (ie, arteriovenous malformations and fistulas) could trigger “neurovascular uncoupling” in those patients. Neurovascular uncoupling, and other pitfalls of fMRI, are briefly discussed.
David Mikulis discusses “neurovascular uncoupling syndrome,” where lack of functional hyperemia during neuronal activation can have long-term consequences on the integrity of the tissue in the absence of acute ischemia.
Jay Pillai discusses the successful clinical application of a technique to improve the consistency of BOLD fMRI by using a breath-holding technique.
Aaron Field discusses the technique, clinical use, and some limitations of DTI and tractography, and describes patterns of alteration of white matter fiber tracts by neoplasms and other lesions.
Lastly, Wade Mueller shows that a neurosurgeon may obtain significant improvements in clinical outcomes and a drastic reduction in complication rates when working with a team that provides presurgical mapping of cerebral lesions by using fMRI and DTI (wisely, fully acknowledging their limitations) and when various team members clearly communicate using a common language.
Functional MRI and DTI are extremely useful techniques that have become increasingly available to neuroradiologists in recent years. As with any technique, these work best as parts of a whole. A good understanding of physiologic mechanisms is necessary to make us good “functional” specialists, and a good understanding of the limitations of any technique is necessary to make us better physicians.
Image modified from: Jellison BJ, Field AS, Medow J, et al. Diffusion tensor imaging of cerebral white matter: a pictorial review of physics, fiber tract anatomy, and tumor imaging patterns.
为满足广大用户对功能磁共振成像技术(fMRI)的应用需求,帮助磁共振脑成像领域临床医生、科研工作者、研究生群体快速掌握脑功能课题的实验任务设计、影像数据处理和分析的基本原理和实操方法。4月12日至14日,由美德医疗主办的第13届Task-fMRI基础培训班在深圳总部成功举办!特邀深圳大学心理学院成晓君教授、王超教授、林正龙教授等一线青年学者进行授课,讲解fMRI的基础知识,介绍常用数据处理工具,带教实验设计、任务编写和数据处理全流程操作,采用了实践操作与理论讲解相结合的教学方式,注重培养学员的自主操作能力,帮助学员们深入理解Task-fMRI技术的原理和应用。培训班济济一堂,广大学员皆对脑科学有着高度的学习热情和探究精神,为Task-fMRI相关知识和技能的掌握及应用,奠定了坚实的基础。为期三天紧凑而丰富的教学及实操课程,让一众学员们表示受益匪浅,更是积极与讲师深入交流解己所惑。未来,美德医疗将继续开展影像技术培训,促进相关知识和技能的普及和应用,并持续将客户需求转化到产品优化与技术服务!
重大喜讯,2024年04月07日,美德医疗自主研发的“磁共振病人监护仪”成功获批广东省药品监督管理局颁发的《医疗器械注册证》。该产品的上市,标志着美德医疗成为国产无磁监护领域首家注册上市的企业,不仅彰显了我司对磁兼容医疗设备研发的专业技术实力,也意味着美德医疗迈入了一个更高标准、更高起点、更高层次的新平台,为更多的患者和医疗机构提供磁共振环境下安全、高效、先进的整体解决方案!未来,我们将不断提升产品质量和服务水平,继续加大研发投入,推动技术创新和产品升级,为医疗影像事业的发展贡献更多的智慧和力量!
2024年3月29日-31日,由电子科技大学生命科学与技术学院、四川省医学科学院∙四川省人民医院联合主办的“首届天府孤独症脑科学国际论坛”在电子科技大学清水河校区成功举办。本次会议邀请了从事孤独症研究的神经科学、遗传学、心理认知学和临床、康复领域的国内外知名专家,面向广大关注孤独症的科研人员、临床医生和相关家庭,从行为、分子、环路、脑影像及医学干预与行为矫正等多层面解析孤独症的机制及精确诊断与治疗的前沿方法。大会还组织家长-专家圆桌讨论,为孤独症家庭与孤独症研究领域专家们提供面对面探讨的机会,以及举办“星星集市”、“湖畔音乐会”等公益活动,展示“来自星星的孩子”的独特艺术天赋。美德医疗特别赞助本次会议,并携脑科学相关产品亮相现场,吸引了诸多学者同仁前来交流,不少在场的老师和医生对美德医疗脑功能视听觉刺激仪在科研及临床上的贡献给出了高度评价。未来,美德医疗将坚持科学探索,不断优化产品,为推进国内孤独症研究领域多学科协同发展,促进孤独症脑影像技术产学研用成果转化贡献力量!
随着社会就业形势日渐严峻,国家大力加强关于促进高校毕业生就业的工作部署,为积极响应国家政策,贯彻产教融合与高校共谋发展,我司也迎来了深圳技术大学健康与环境工程学院副院长康雁教授等一众老师及学生的访企拓岗促就业专项行动。美德医疗创始人汤洁女士对康教授一行人的到访表示热烈欢迎,通过共同参观我司的文化展厅、研发中心、生产仓储等实体产业规模,向大家详细介绍了美德的成长历程、企业文化、专研领域、公司荣誉、发展方向等等。在充分了解美德目前的发展现状之后,双方就我司的人才需求结合学校的人才培养展开了深入的交流,作为深圳专精特新的技术企业,我司由磁共振第三方部件源头制作供应,对产业链前端-硬件的研发极其看重。美德大家庭的每一位成员,对公司有着极高的认同和归属感,钻研与热爱并行,技能与素养同在。借此交流机会,希望能与深圳技术大学加强合作共同培养专项人才,贴近技术发展契合市场需求,为学生的实习实训就业提供更多机会,实现校企紧密联系、资源共享、合作共赢!
2024年2月9日,《Human Brain Mapping》期刊在线发表了题为《Phase-encoded fMRI tracks down brainstorms of natural language processing with subsecond precision》的研究论文,该研究由澳门大学认知与脑科学中心、圣地亚哥州立大学心理学系共同完成。研究人员使用实时相位编码 (phase-encoded) 功能磁共振成像 (functional magnetic resonance imaging, fMRI) 技术,通过多种形式(听、说、默读、记忆)语言任务刺激被试,绘制出语言处理过程中的全脑动态图,揭示了不同的大脑区域在语言感知和产生过程中如何相互作用。由于MR扫描噪音、说话引起的头动会造成图像伪影,影响MRI成像效果。在正式扫描前,研究人员使用深圳美德医疗自主研发生产的模拟磁共振对被试进行扫描训练,让被试在说话时可以保持头部不动,极大地提高了实验效率与图像质量。美德模拟磁共振 (http://www.sinorad.com/pro-show-478.html ) 提供了一个类似于真实MRI扫描的空间环境,用于被试在真实扫描开始前进行模拟演练。通过模拟磁共振的扫描演练,被试既可以适应MR扫描噪音、减少头动从而提高图像质量,又可以熟悉MR扫描流程,减少磁共振资源浪费。模拟磁共振还可以用来进行预实验,以检测实验设计的合理性、有效性。美德医疗专注fMRI设备研发、咨询及培训20年,客户分布广泛,包括港澳台地区在内的300余家高校、科研院所、医院,获得业内广泛认可,对fMRI技术在中国的发展及临床应用起到重要推动作用。 文章链接:https://onlinelibrary.wiley.com/doi/full/10.1002/hbm.26617